

# Pharmacy and Therapeutics Committee

## Meeting Minutes

Thursday, November 21, 2019

7:00 a.m. to 8:45 a.m.  
Cannon Health Building  
Room 125

### Committee Members Present:

McKay Robinson, PharmD  
Cole Sloan, PharmD  
Michelle Hofmann, MD  
Susan Siegfried, MD

Bryan Larson, PharmD  
Clayton Grace, RPh  
Clinton Sheffield, MD  
Christopher Valentine, MD

### Committee Members Excused:

Elizabeth Young, PharmD

### Dept. of Health/Div. of Health Care Financing Staff Present:

Jennifer Strohecker, PharmD, Pharmacy  
Director  
Joe Busby, RPh, MBA

Mohit Bhakta, PharmD  
Ngan Hyunh, PharmD  
Spencer Miller, CPhT

### University of Utah Drug Regimen Review Center Staff Presenter:

Elena Martinez Alonso, B.S. Pharm, MSc MTSI, Medical Writer

### Other Individuals Present:

Cody Ball, Select Health  
Jason Bott, Lilly  
Valerie Gonzales, U of U  
Jonny Sandoval, U of U  
Karlee Paloukos, U of U  
Joseph Lambson, U of U  
Lisa Wilson, Biogen  
Evan Riddle, Biogen  
Randi Lewandowski, EMD Serono

Robb Host, Neurelis  
Kendra Larsen, U of U  
Jennifer Lauper, Bristol-Myers Squibb  
Paul Williams, Tricida  
Gina Soto, Alkermes  
Marlies Ozias, Bristol-Myers Squibb  
Hayden Shuster, Bristol-Myers Squibb  
Jenna Gianninoto, AbbVie

Meeting conducted by: Committee Chair

---

1. **Welcome & Housekeeping:** McKay Robinson opened the meeting and reminded everyone to sign the rosters.
2. **Review and Approval of September Minutes:** Clinton Sheffield made a motion to approve the minutes from September. Clayton Grace seconded the motion. All in favor, motion passed.

# Pharmacy and Therapeutics Committee

## Meeting Minutes

Thursday, November 21, 2019

3. **Drug Utilization Review (DUR) Board update:** The DUR board met last week to discuss Zulresso as well as pediatric antipsychotics.
4. **Cytokine Modulators:** Mohit Bhakta presented a review of Cytokine Modulators to continue the discussion from the September 2019 meeting.
5. **Public Comment:**
  - a. Marlies Ozias from Bristol-Myers Squibb presented information pertaining to Orencia (Abatacept).
  - b. Jema Giaminoto from AbbVie presented information pertaining to Rinvoq (upadacitinib).
6. **Committee Discussion:** Susan Siegfried made a motion to include at least 2 cytokine modulators, including at least one TNF-Alpha inhibitor as preferred on the PDL. Clinton Sheffield seconded. Unanimous approval, motion passed.
7. **Multiple Sclerosis Review: Elena Martinez** provided a review of agents to treat Multiple Sclerosis. **Mohit Bhakta presented** guidelines, and information on other states' preferred drug lists, and presented recommendations.
8. **Public Comment:**
  - a. Caroline Kicklighter from Novartis presented information pertaining to Mayzent (siponimod).
  - b. Even Riddle from Biogen presented information pertaining to a variety of Biogen drugs used for Multiple Sclerosis.
9. **Committee Discussion:** Susan Siegfried made a motion that those individuals currently on medications that were previously approved be grandfathered and allowed to continue those medications that they are currently on. Cole Sloan seconded. Unanimous approval, motion passed.

Bryan Larson made a motion to have at least one highly effective agent as preferred, at least one moderately effective agent as preferred, at least one oral agent as preferred, and at least one agent for use in pregnancy as preferred; and that cladribine, alemtuzumab, mitoxantrone are less safe agents in this class. McKay Robinson seconded. All in favor, motion passed.

Cole Sloan made a motion to define modestly efficacious first line DMT is defined as interferon beta products, glatiramer, teriflunomide, and dimethyl fumarate, and diroximel fumarate. Highly efficacious second-line DMT is defined as alemtuzumab, cladribine, fingolimod, mitoxantrone, natalizumab, ocrelizumab, dimethyl fumarate, and diroximel fumarate. Clinton Sheffield seconded. All in favor, motion passed.

# Pharmacy and Therapeutics Committee

## Meeting Minutes

Thursday, November 21, 2019

10. **Public Meeting Adjourned:** McKay Robinson motioned to close the meeting. Bryan Larson seconded the motion. All in favor, motion passed.

11. **Next meeting is scheduled for** March 19, 2020 Cystic Fibrosis Gene Therapies.

---

Audio recording of all P&T meetings are available online at:

<https://medicaid.utah.gov/pharmacy/pt-committee?p=Committee%20Meeting%20Audio%20Recordings>